# BioNTech and Bristol Myers Squibb Report 36.7% Confirmed Response Rate for Pumitamig in Advanced NSCLC > BioNTech and Bristol Myers Squibb reported a 36.7% confirmed objective response rate for pumitamig plus docetaxel in advanced NSCLC. - Published: 2026-10-25T07:55:42+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-10-25/biontech-bristol-myers-pumitamig-lung-cancer-data - Source: [TradingView](https://www.tradingview.com/news/globenewswire:e3fc43618094b:0-biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-data-for-pumitamig-in-advanced-nsclc-after-progression-on-immunotherapy-plus-chemotherapy/) ## Key takeaways - Pumitamig plus docetaxel produced a confirmed objective response rate of 36.7% among 30 efficacy-evaluable patients in the ROSETTA Lung-107 Phase 2 trial. - Median progression-free survival was 6.9 months in the 50-patient treated population, with a six-month PFS rate of 63.3%. - BioNTech and Bristol Myers Squibb are running seven global Phase 3 trials of pumitamig, including four in lung cancer. [BioNTech](https://akta.pro/company-profiles/0000j4h/biontech) and Bristol Myers Squibb reported a confirmed objective response rate of 36.7% for pumitamig plus docetaxel in metastatic non-small cell lung cancer that progressed on or after first-line immunotherapy plus chemotherapy, with a median progression-free survival of 6.9 months. The companies announced the Phase 2 data on October 25, 2026, according to [TradingView](https://www.tradingview.com/news/globenewswire:e3fc43618094b:0-biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-data-for-pumitamig-in-advanced-nsclc-after-progression-on-immunotherapy-plus-chemotherapy/). ## How the ROSETTA Lung-107 Trial Worked The global, open-label, single-arm Phase 2 ROSETTA Lung-107 trial (NCT06841055) evaluated pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator also known as BNT327 or BMS986545, in combination with docetaxel in patients with stage IV squamous or non-squamous NSCLC whose disease progressed after first-line immunotherapy plus chemotherapy, with any level of PD-L1 expression. The July 10, 2026, data cut-off included 50 patients with a median follow-up of 12.2 weeks, and 33 patients remained on treatment. Among 30 efficacy-evaluable patients, the confirmed objective response rate was 36.7% with a disease control rate of 90.0%, and responses were observed across PD-L1 expression levels and histologies. Median time to response was 1.4 months, and in the overall treated population median progression-free survival was 6.9 months with a six-month PFS rate of 63.3%. The data were presented in a late-breaking rapid oral presentation (abstract #LBA76) at the European Society for Medical Oncology Congress 2026 in Madrid, Spain. "These first data from ROSETTA Lung-107 show encouraging response rates and progression-free survival across PD-L1 expression levels and histology, suggesting that pumitamig may help re-engage antitumor immunity in patients who have progressed on prior immunotherapy plus chemotherapy," said Byoung Chul Cho, M.D., Ph.D., Trial Investigator and Professor of Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Bristol Myers Squibb and BioNTech formed a global strategic partnership in May 2024 for co-development and co-commercialization of the PD-L1xVEGF-A bispecific antibody across numerous solid tumor types, a deal valued at up to $11.1 billion including $1.5 billion upfront and $9.6 billion in milestones, according to [akta.pro company records](https://akta.pro/company-data). ## BioNTech's Pumitamig Development Program BioNTech is a German biopharmaceutical firm developing mRNA immunotherapies for cancer and infectious diseases, including the Comirnaty COVID-19 vaccine with Pfizer, and is pivoting from COVID-19 manufacturing to an oncology pipeline of bispecific antibodies, mRNA cancer vaccines, and antibody-drug conjugates, according to akta.pro company records. More than 4,000 patients have been treated with pumitamig in clinical trials to date, and seven global Phase 3 trials with registrational potential are ongoing, including four in lung cancer. BioNTech reported cash reserves of €16.8 billion as of Q1 2026 and 2026 revenue guidance of €2.0-2.3 billion, down from €2.9 billion in 2025. ## Earlier BioNTech Oncology Updates On October 19, 2026, BioNTech said it would present 16 abstracts at ESMO 2026, including first data from the global ROSETTA Lung-107 Phase 2 trial of pumitamig plus docetaxel in metastatic NSCLC, according to TradingView. On October 22, 2026, BioNTech announced a collaboration with Gilead to evaluate pumitamig with sacituzumab govitecan in a Phase 3 trial for triple-negative breast cancer, with the trial replacing chemotherapy with the TROP2-directed ADC pending regulatory approval, according to Stock Titan. On October 19, 2026, BioNTech's AHEAD-MERIT trial of BNT113 plus pembrolizumab versus pembrolizumab alone in HPV16-positive HNSCC did not meet its PFS primary endpoint, with no significant difference between arms, according to 医药魔方. ## What Comes Next for Pumitamig Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, said the companies "look forward to defining the path forward for pumitamig in second-line NSCLC." The companies said the ROSETTA Lung-107 data will inform further development of pumitamig in this patient population. ## Companies in this story - [BioNTech company profile](https://akta.pro/company-profiles/0000j4h/biontech) · website: https://www.biontech.com/int/en/home.html --- News for Agent · https://newsforagent.com/llms.txt